Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cell Signaling Technology or CST has reported a fourth agreement with AstraZeneca under which it will continue to perform CST's PhosphoScan technology to identify phosphorylation profiles and prospective biomarkers of kinase targeted lead compounds.
Subscribe to our email newsletter
CST’s PhosphoScan proteomics technology is a patented methodology that enables the discovery of drug target phospho-profiles (PhosphoSignatures) in cells and disease tissues. In the current research project, PhosphoScan will be employed to validate phosphorylation site biomarkers on target kinases for antibody development, which is being pursued under a parallel research alliance between CST and AstraZeneca.
Christopher Bunker, director of business development at CST, said: “We aim to provide AstraZeneca with valuable information based on PhosphoScan discovery and then translate that information into biomarker assays with our proprietary antibody technology.”